^
Association details:
| Biomarker: | FGF19 positive |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Balversa (erdafitinib) (FGFR inhibitor, FGFR1 inhibitor, FGFR4 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
Published date:
09/30/2022
Excerpt:
...the pan-FGFR inhibitor erdafitinib displayed superior potency than FGFR4-selective inhibitors in suppressing the growth and survival of FGF19-positive HCC cells.
DOI:
https://doi.org/10.1073/pnas.2208844119
